CNS drug development: Part II: Advances from the 1960s to the 1990s

Journal of Psychiatric Practice

Volumn 16, Issue 6, 2010, Pages 413-415

  Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

animal models of psychiatric illness; antidepressants; antipsychotics; central nervous system drugs; drug development; drug discovery

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIOGENIC AMINE; CENTRAL NERVOUS SYSTEM AGENTS; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PHENOTHIAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISTORY OF MEDICINE; HUMAN; MENTAL DISEASE; NONHUMAN; PSYCHOPHARMACOLOGY; PSYCHOSIS; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DEPRESSIVE DISORDER; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HUMANS; MODELS, ANIMAL;

EID: 78650358004     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000390760.12204.99     Document Type: Article

References (13)

1. Preskorn SH. CNS drug development: Part I: The early period of CNS drugs. J Psychiatric Pract 2010;16:334-9.
2. The Nobel Prize in Physiology for Medicine 1970: Sir Bernard Katz, Ulf von Euler, Julius Axelrod. Julius Axelrod: Biography The official website of the Nobel Prize, available at nobelprize.org/nobel-prizes/medicine/laure-ates/1970/ axelrod-bio.html, accessed October 4, 2010.
3. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psy-chosis: Theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 2001;34:689-700.
4. Geyer M, Moghaddam B. Animal models relevant to schiz-ophrenia disorders. In: Davis, KL, Charney D, Coyle JT, et al., eds. Neuropsychopharmacology: The fifth generation of progress. Philadelphia: Lippincott, Williams, & Wilkins; 2002:689-701.
5. Ayd JF, ed. Haloperidol update: 1958-1980. Baltimore: Ayd Medical Communications 1980.
6. Iversen LL, Iversen SD, Bloom FE, et al. eds. Introduction to neuropsychopharmacology Oxford, United Kingdom: Oxford University Press; 2008.
7. Preskorn SH. A roadmap to key pharmacologic principles in using antipsychotics: Application in clinical practice. J Clin Psychiatry 2009;70:593-600.
8. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002;47:27-38.
9. Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle, J Psychiatr Pract 2001; 7:209-13.
10. Preskorn SH. Outpatient management of depression, 3rd edition. Caddo, OK: Professional Communications; 2009.
11. Preskorn SH, Irwin, HA. Toxicity of tricyclic antidepres-sants\kinetics, mechanism, intervention: A review. J Clin Psychiatry 1982;43:151-6.
12. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, Caddo, OK: Professional Communica-tions; 1996.
13. Preskorn SH. Results of the STAR*D study: Implications for clinicians and drug developers. J Psychiatr Pract 2009; 15:45-9.